Zevia (ZVIA)
(Delayed Data from NYSE)
$1.05 USD
+0.03 (2.94%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $1.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.05 USD
+0.03 (2.94%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $1.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Zacks News
Zevia (ZVIA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevia (ZVIA) delivered earnings and revenue surprises of 30.77% and 2.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zevia (ZVIA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zevia (ZVIA) delivered earnings and revenue surprises of 0% and 2.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 4.55% and 0.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 125% and 1.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
After Plunging -22.28% in 4 Weeks, Here's Why the Trend Might Reverse for Zevia (ZVIA)
by Zacks Equity Research
Zevia (ZVIA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
New Strong Buy Stocks for July 26th
by Zacks Equity Research
ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.
What Makes Zevia (ZVIA) a New Strong Buy Stock
by Zacks Equity Research
Zevia (ZVIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for July 13
by Zacks Equity Research
ACVA, MDB and ZVIA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2023.
Zevia (ZVIA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevia (ZVIA) delivered earnings and revenue surprises of 76.47% and 3.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 32.35% and 6.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zevia (ZVIA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevia (ZVIA) delivered earnings and revenue surprises of 16.67% and 15.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zevia (ZVIA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zevia (ZVIA) delivered earnings and revenue surprises of 19.05% and 7.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -55.56% and 0.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zevia (ZVIA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevia (ZVIA) delivered earnings and revenue surprises of -55.56% and 7.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -755% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 38.78% and 590.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?